Evidence map›Paper›PMID 38792187›Full record

ReviewMolecules (Basel, Switzerland)2024

A New 2-Aminospiropyrazolylammonium Cation with Possible Uses in the Topical Areas of Ionic Liquids.

Lyudmila Kayukova, Anna Vologzhanina

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Lyudmila KayukovaLaboratory of Chemistry of Synthetic and Natural Drug Substances, JSC A.B. Bekturov Institute of Chemical Sciences, 106 Shokan Ualikhanov Str., 050010 Almaty, Kazakhstan.ORCID 0000-0002-1900-1228
Anna VologzhaninaX-ray Diffraction Laboratory, A.N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, 28 Vavilov Str., B-334, 119334 Moscow, Russia.ORCID 0000-0002-6228-303X

Funding

Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan ИРН АР14870011
6 · The paper itself

Abstract

Based on the fact that 2-aminospiropyrazolinium compounds and structurally related azoniaspiro compounds belong, in a broad sense, to the class of ionic liquids, we have reviewed them and studied their practical applications. To search for possible uses of a new 2-aminospiropyrazolinium compounds, it is necessary to undertake a comparison with the related class of azoniaspiro compounds based on available information. The structures of the well-studied class of azoniaspiro compounds and the related but little-studied class of 2-aminospiropyrazolinium have rigid frameworks, limited conformational freedom, and a salt nature. These properties give them the ability to organize the nearby molecular space and enable the structure-forming ability of azoniaspiro compounds in the synthesis of zeolites, as well as the ability to act as phase-transfer catalysts and have selective biological effects. Additionally, these characteristics enable their ability to act as electrolytes and serve as materials for anion exchange membranes in fuel cells and water electrolyzers. Thus, the well-studied properties of azoniaspiro compounds as phase-transfer catalysts, structure-directing agents, electrolytes, and materials for membranes in power sources would encourage the study of the similar properties of 2-aminospiropyrazolinium compounds, which we have studied in relation to in vitro antitubercular, antidiabetic, and antimicrobial activities.

Indexed as

2-aminospiropyrazolinium structuresazoniaspiro compoundsin vitro biological activitiesionic liquidsmembranes in the current sourcesphase-transfer catalystsstructure-forming agents

Identifiers

PMID38792187
PMCPMC11124009

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.